Our Strategic Plan has been developed to rapidly and systematically address and remove the critical barriers and challenges that are slowing down or preventing the research, development and access to new effective treatments, optimal care, support and information.
As a bench-to-bedside and back again approach, we are doing everything we can to ensure that the next generation of myeloma treatments are available to patients in the clinic as quickly as possible. By injecting funding, speed and efficiency into the critical steps of the drug discovery, development and approval process we are transforming the way in which myeloma is researched, treated and managed.
In addition, we work to ensure that patients and their families have access to the best possible care, information and support they need, where and when they need it.
Patients, their families and carers are at the centre of everything we do. We work tirelessly and relentlessly on their behalf.